サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606423

ネオアンチゲンがんワクチン市場：製品別、タイプ別、投与経路別、送達メカニズム別、用途別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年

Neoantigen Cancer Vaccine Market, By Product, By Type, By Route of Administration, By Delivery Mechanism, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 317 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ネオアンチゲンがんワクチン市場：製品別、タイプ別、投与経路別、送達メカニズム別、用途別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 317 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

ネオアンチゲンがんワクチン市場規模は2023年に460億5,943万米ドルとなり、2024年から2032年にかけてCAGR 73.40%で拡大

ネオアンチゲンがんワクチン市場-市場力学

患者の治療をカスタマイズすることを目的とした個別化医療の採用が増加しており、市場の拡大を促進すると予測されています。このアプローチは、遺伝子プロファイル、腫瘍の特徴、全体的な健康状態など、個々の患者の特徴に合わせて特別に設計された治療計画の開発に重点を置いています。この手法の中心となるのがネオアンチゲンワクチンで、患者の腫瘍に見られる明確な変異に基づいて綿密に作られます。注目すべきは、市場で利用可能な個別化医薬品の数が132から286に増加し、これらの治療法は2019年にFDAによって承認された新薬の25％を占めていることです。

さらに、製薬会社やベンチャーキャピタルからの出資を含む、官民双方からの資金提供の強化が、この領域における研究開発の取り組みを後押ししています。とはいえ、製造工程の複雑さが市場成長の課題となる可能性もあります。

ネオアンチゲンがんワクチン市場-主要インサイト

リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約73.40%のCAGRで毎年成長すると推定されます。

製品別では、パーソナライズドは2023年に最大市場シェアを示すと予測されました。

タイプ別では、核酸が2023年の主要タイプでした。

用途別では、肺がんが2023年の主要タイプでした。

地域別では、北米が2023年の主要収益源であった

ネオアンチゲンがんワクチン市場-セグメンテーション分析：

ネオアンチゲンがんワクチンの世界市場は、製品、タイプ、投与経路、送達メカニズム、用途、地域に基づいて区分されます。

市場は製品によって2つのセグメントに分類される：個別化（Personalized）と市販（Off-the-shelf）です。パーソナライズドセグメントは、市場で圧倒的な地位を占めています。個別化ネオアンチゲンワクチンは、免疫反応を高めるためにPD-1やCTLA-4阻害剤などのチェックポイント阻害剤と併用されることが多いです。この組み合わせ戦略は、既存の免疫療法の欠点に対処し、患者の予後を改善するために検討されています。

市場はタイプ別に4つのカテゴリーに分類される：樹状細胞、核酸、合成ロングペプチド、腫瘍細胞です。核酸カテゴリーが市場をリードしています。ネオアンチゲンがんワクチン市場は、核酸技術の進歩、特に腫瘍特異的変異への対処を目的とした新規ワクチンの創出に大きく関連しています。

市場は投与経路によって3つのカテゴリーに区分される：筋肉内投与、静脈内投与、経皮投与です。ネオアンチゲンがんワクチン市場は大きな成長を遂げており、これらのテーラーメイド治療の進歩と流通にはさまざまな投与経路が不可欠です。

市場は送達メカニズムによって4つのセグメントに分類される：リポソーム、バイロソーム、遺伝子ガン、エレクトロポレーション、その他です。これらのメカニズムは、個別化ワクチンを標的細胞に効果的に送達し、がん特異的新抗原に対する強固な免疫反応を促進するために不可欠です。

市場は用途によって4つのカテゴリーに分類される：脳腫瘍、消化器がん、肺がん、黒色腫、その他です。肺がんは市場の主導的地位を占めています。肺がんの場合、変異の負荷が高いため、標的となる潜在的なネオアンチゲンが多様に存在し、個別化ワクチンが有望なアプローチとして位置づけられています。

ネオアンチゲンがんワクチン市場-地理的洞察

北米は強固な臨床試験の枠組みを特徴としており、多数の研究機関や病院がネオアンチゲンワクチンの開発に従事しています。この地域の規制状況は、合理化された臨床試験プロセスを促進し、革新的な治療法の進歩と評価を促進しています。米国では、がんはほぼすべての人々に影響を及ぼしており、がん研究への資金援助拡大に対する国民の支持は大きいです。ASCOが4,000人以上の米国人を対象に実施した最近の調査では、約73％が、増税や国家赤字の増加が必要であっても、政府はがんの治療法や治療法の発見にもっと多くの資源を配分すべきだと考えていることが明らかになった。欧州は、ゲノム技術の進歩に牽引され、市場拡大が見込まれる第2位の地域です。全体として、ネオアンチゲンがんワクチンの世界の環境は活気に満ちており、さまざまな地域に数多くの成長機会をもたらしています。

ネオアンチゲンがんワクチン市場-競合情勢：

ネオアンチゲンがんワクチン市場は、大手企業が最先端技術を積極的に活用し、戦略的提携を確立し、研究開発に多額の投資を行っており、非常に競争的な環境を示しています。これらの企業は、研究機関やヘルスケア施設、他のバイオテクノロジー企業と協力して研究開発を強化し、ネオアンチゲンワクチンの創出を加速させています。競合情勢は、絶え間ない技術の進歩や患者の予後向上への取り組みによって、急速に変化していくと予想されます。

目次

第1章 ネオアンチゲンがんワクチン市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 ネオアンチゲンがんワクチンの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 ネオアンチゲンがんワクチン産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 ネオアンチゲンがんワクチン市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 ネオアンチゲンがんワクチン市場情勢

  • ネオアンチゲンがんワクチン市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 ネオアンチゲンがんワクチン市場- 製品別

  • 概要
    • セグメントシェア分析
    • 個別化
    • 市販

第8章 ネオアンチゲンがんワクチン市場- タイプ別

  • 概要
    • セグメントシェア分析
    • 樹状細胞
    • 核酸
    • 合成長鎖ペプチド
    • 腫瘍細胞

第9章 ネオアンチゲンがんワクチン市場- 投与経路別

  • 概要
    • セグメントシェア分析
    • 筋肉内
    • 静脈内
    • 経皮

第10章 ネオアンチゲンがんワクチン市場- 送達メカニズム別

  • 概要
    • セグメントシェア分析
    • リポソーム
    • ヴィロソーム
    • 遺伝子ガン
    • エレクトロポレーション
    • その他

第11章 ネオアンチゲンがんワクチン市場- 用途別

  • 概要
    • セグメントシェア分析
    • 脳腫瘍
    • 消化器がん
    • 肺がん
    • 悪性黒色腫
    • その他

第12章 ネオアンチゲンがんワクチン市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析- ネオアンチゲンがんワクチン業界

  • 競合ダッシュボード
  • 企業プロファイル
    • OSE Immunotherapeutics SA
    • Gritstone bio Inc.
    • BioNTech SE
    • Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Merck &Co. Inc.
    • Moderna Inc.
    • Avidea Technologies Inc.
    • Eli Lilly and Company
    • Vaccibody AS
    • Agenus Inc.
    • Novogene Co. Ltd.
    • ZIOPHARM Oncology Inc.
    • ISA Pharmaceuticals BV
    • BrightPath Biotherapeutics Co. Ltd.
    • Vaximm AG
    • Medigene AG
    • Genocea Biosciences Inc.
    • Advaxis Inc.
    • Nouscom AG
    • Others

第14章 アナリストの全方位展望

目次
Product Code: ANV4229

REPORT HIGHLIGHT

The Neoantigen Cancer Vaccine Market size was valued at USD 46,059.43 million in 2023, expanding at a CAGR of 73.40% from 2024 to 2032.

Neoantigen cancer vaccines constitute a form of personalized immunotherapy aimed at activating the immune system to identify and combat cancerous cells. These vaccines focus on neoantigens, which are unique antigens generated from mutations within tumor cells. The development of neoantigen cancer vaccines marks a notable progression in the field of cancer immunotherapy, utilizing the distinct features of an individual's tumor to bolster the body's inherent capacity to combat cancer.

Neoantigen Cancer Vaccine Market- Market Dynamics

The growing adoption of personalized medicine aimed at customizing patient treatment is anticipated to propel market expansion. This approach emphasizes the development of treatment plans that are specifically designed to align with individual patient characteristics, such as genetic profiles, tumor features, and overall health status. Central to this methodology are Neoantigen vaccines, which are meticulously crafted based on the distinct mutations found in a patient's tumor. Notably, the number of personalized medicines available in the market increased from 132 to 286, with these therapies representing 25% of the new drugs approved by the FDA in 2019.

Moreover, enhanced funding from both public and private sectors, including contributions from pharmaceutical companies and venture capitalists, is driving research and development efforts in this domain. Nevertheless, the complexity of manufacturing processes may pose challenges to market growth.

Neoantigen Cancer Vaccine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 73.40% over the forecast period (2024-2032)

Based on Product segmentation, Personalized was predicted to show maximum market share in the year 2023

Based on Type segmentation, Nucleic Acid was the leading type in 2023

Based on Application segmentation, Lung Cancer was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Neoantigen Cancer Vaccine Market- Segmentation Analysis:

The Global Neoantigen Cancer Vaccine Market is segmented based on Product, Type, Route of Administration, Delivery Mechanism, Application, and Region.

The market is classified into two segments according to product: Personalized and Off-the-shelf. The Personalized segment holds a dominant position in the market. Personalized neoantigen vaccines are frequently used in conjunction with checkpoint inhibitors, such as PD-1 or CTLA-4 inhibitors, to enhance the immune response. This combinatorial strategy is under investigation to address the shortcomings of existing immunotherapies and to enhance patient outcomes.

The market is segmented into four categories according to type: Dendritic Cell, Nucleic Acid, Synthetic Long Peptide, and Tumor Cell. The Nucleic Acid category holds a leading position in the market. The Neoantigen Cancer Vaccine Market is significantly linked to progress in nucleic acid technologies, especially in the creation of novel vaccines aimed at addressing tumor-specific mutations.

The market is segmented into three categories according to the Route of Administration: Intramuscular, Intravenous, and Transdermal. The Neoantigen Cancer Vaccine Market is experiencing significant growth, with different routes of administration being essential for the advancement and distribution of these tailored therapies.

The market is categorized into four segments according to the Delivery Mechanism: Liposomes, Virosomes, Gene gun, Electroporation, and Others. These mechanisms are essential for effectively delivering personalized vaccines to the targeted cells, thereby facilitating a robust immune response to the cancer-specific neoantigens.

The market is segmented into four categories according to application: Brain Cancer, Gastrointestinal Cancer, Lung Cancer, Melanoma, and Others. Lung Cancer holds a leading position in the market. In the case of lung cancer, the elevated mutation burden offers a diverse range of potential neoantigens for targeting, thereby positioning personalized vaccines as a highly promising approach.

Neoantigen Cancer Vaccine Market- Geographical Insights

North America features a robust clinical trial framework, with a multitude of research institutions and hospitals engaged in the development of Neoantigen vaccines. The regulatory landscape in this region facilitates streamlined trial processes, promoting the advancement and evaluation of innovative therapies. Cancer has impacted nearly every individual in the United States, and there is significant public support for increased funding in cancer research. A recent survey conducted by ASCO, involving over 4,000 Americans, revealed that approximately 73% believe the government should allocate more resources to discovering treatments and cures for cancer, even if this necessitates higher taxes or an increase in the national deficit. Europe represents the second largest region for market expansion, driven by advancements in genomic technologies. Overall, the global environment for Neoantigen cancer vaccines is vibrant, presenting numerous growth opportunities across different regions.

Neoantigen Cancer Vaccine Market- Competitive Landscape:

The Neoantigen cancer vaccine market exhibits a highly competitive environment, with major players actively utilizing cutting-edge technologies, establishing strategic alliances, and making significant investments in research and development. These companies are collaborating with research institutions, healthcare facilities, and other biotechnology firms to strengthen their R&D efforts and accelerate the creation of neoantigen vaccines. The competitive landscape is expected to change swiftly, driven by continuous technological advancements and a commitment to enhancing patient outcomes.

Recent Developments:

On September 10, 2024, OSE Immunotherapeutics SA announced the commencement of its international Phase 3 clinical trial, named 'Artemia,' for Tedopi, a therapeutic cancer vaccine based on neoepitopes intended for off-the-shelf application. This trial is aimed at providing second-line treatment for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). The study has received review and approval from health authorities across 14 countries, including the US FDA, Canada, Europe, and the United Kingdom, marking a significant advancement in the registration process for Tedopi, in conjunction with the development of a companion diagnostic for HLA-A2 positive patients.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEOANTIGEN CANCER VACCINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • OSE Immunotherapeutics SA
  • Gritstone Bio Inc.
  • BioNTech SE
  • Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Moderna Inc.
  • Avidea Technologies Inc.
  • Eli Lilly and Company
  • Vaccibody AS
  • Agenus Inc.
  • Novogene Co. Ltd.
  • ZIOPHARM Oncology Inc.
  • ISA Pharmaceuticals B.V.
  • BrightPath Biotherapeutics Co. Ltd.
  • Vaximm AG
  • Medigene AG
  • Genocea Biosciences Inc.
  • Advaxis Inc.
  • Nouscom AG
  • Others

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • Personalized
  • Off-the-shelf

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Dendritic Cell
  • Nucleic Acid
  • Synthetic Long Peptide
  • Tumor Cell

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intramuscular
  • Intravenous
  • Transdermal

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY DELIVERY MECHANISM- MARKET ANALYSIS, 2019 - 2032

  • Liposomes
  • Virosomes
  • Gene gun
  • Electroporation
  • Others

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Brain Cancer
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma
  • Others

GLOBAL NEOANTIGEN CANCER VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neoantigen Cancer Vaccine Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neoantigen Cancer Vaccine Market Snippet by Product
    • 2.1.2. Neoantigen Cancer Vaccine Market Snippet by Type
    • 2.1.3. Neoantigen Cancer Vaccine Market Snippet by Route of Administration
    • 2.1.4. Neoantigen Cancer Vaccine Market Snippet by Delivery Mechanism
    • 2.1.5. Neoantigen Cancer Vaccine Market Snippet by Application
    • 2.1.6. Neoantigen Cancer Vaccine Market Snippet by Country
    • 2.1.7. Neoantigen Cancer Vaccine Market Snippet by Region
  • 2.2. Competitive Insights

3. Neoantigen Cancer Vaccine Key Market Trends

  • 3.1. Neoantigen Cancer Vaccine Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neoantigen Cancer Vaccine Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neoantigen Cancer Vaccine Market Opportunities
  • 3.4. Neoantigen Cancer Vaccine Market Future Trends

4. Neoantigen Cancer Vaccine Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neoantigen Cancer Vaccine Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Neoantigen Cancer Vaccine Market Landscape

  • 6.1. Neoantigen Cancer Vaccine Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neoantigen Cancer Vaccine Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2023 & 2032 (%)
    • 7.1.2. Personalized
    • 7.1.3. Off-the-shelf

8. Neoantigen Cancer Vaccine Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Dendritic Cell
    • 8.1.3. Nucleic Acid
    • 8.1.4. Synthetic Long Peptide
    • 8.1.5. Tumor Cell

9. Neoantigen Cancer Vaccine Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Intramuscular
    • 9.1.3. Intravenous
    • 9.1.4. Transdermal

10. Neoantigen Cancer Vaccine Market - By Delivery Mechanism

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Delivery Mechanism, 2023 & 2032 (%)
    • 10.1.2. Liposomes
    • 10.1.3. Virosomes
    • 10.1.4. Gene gun
    • 10.1.5. Electroporation
    • 10.1.6. Others

11. Neoantigen Cancer Vaccine Market - By Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 11.1.2. Brain Cancer
    • 11.1.3. Gastrointestinal Cancer
    • 11.1.4. Lung Cancer
    • 11.1.5. Melanoma
    • 11.1.6. Others

12. Neoantigen Cancer Vaccine Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Neoantigen Cancer Vaccine Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Neoantigen Cancer Vaccine Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Neoantigen Cancer Vaccine Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Neoantigen Cancer Vaccine Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Neoantigen Cancer Vaccine Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Delivery Mechanism, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Neoantigen Cancer Vaccine Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. OSE Immunotherapeutics SA
    • 13.2.2. Gritstone bio Inc.
    • 13.2.3. BioNTech SE
    • 13.2.4. Hoffmann-La Roche Ltd.
    • 13.2.5. Pfizer Inc.
    • 13.2.6. Merck & Co. Inc.
    • 13.2.7. Moderna Inc.
    • 13.2.8. Avidea Technologies Inc.
    • 13.2.9. Eli Lilly and Company
    • 13.2.10. Vaccibody AS
    • 13.2.11. Agenus Inc.
    • 13.2.12. Novogene Co. Ltd.
    • 13.2.13. ZIOPHARM Oncology Inc.
    • 13.2.14. ISA Pharmaceuticals B.V.
    • 13.2.15. BrightPath Biotherapeutics Co. Ltd.
    • 13.2.16. Vaximm AG
    • 13.2.17. Medigene AG
    • 13.2.18. Genocea Biosciences Inc.
    • 13.2.19. Advaxis Inc.
    • 13.2.20. Nouscom AG
    • 13.2.21. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us